Phillips Medisize

A Phillips Medisize employee working in a pharmaceutical clean room, wearing a lab coat, gloves and protective glasses, he is working on developing inhalation products

Inhalation Product De­vel­op­ment

From one-off studies and specialist techniques to full development services, we are ready to help advance your inhaled program through our tailored inhalation services. Our inhalation services can support your program through all stages of clinical development and device commercial manufacturing.

Flexibility to Meet Your Needs

We understand different customers may require different types of collaborations. You may be a biotech company with an early-phase molecule, looking for fast progression to the clinic and proof-of-concept, or you may be a large pharmaceutical company trying to overcome a technical challenge or looking for a solution to de-risk your program.

With more than 25 years of experience in inhaled product development and a track record of helping customers, partners and licensees succeed in bringing inhaled medicines to market, you can trust us with your product candidate.

We can help your inhaled programs succeed at every stage of product development with:

  • Small molecules and biologics
  • Novel and generic programs

We have a leading range of delivery technologies that you can leverage to create a successful product:

  • Unit-dose and multidose delivery platforms, including proprietary and off-the-shelf device options
  • Conventional and proprietary formulation approaches plus liquid formulations for nebulization
FOX™ Vibrating Mesh Nebulizer from Phillips Medisize
ODD: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Phillips Medisize’s Charlie Schumacher and Sandy Munro discuss the company’s progress on its integration of Vectura. Learn more.
OnDrug Delivery July 2025 cover.
ODD: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson of Phillips Medisize discuss the company’s expanded capabilities as a result of its recent acquisition of Vectura. Learn more.
OIC
PMPS: Elevate Your Molecule
Phillips Medisize’s 2025 acquisition of Vectura expanded its offerings to include inhaled drug development for small molecules, biologics and complex combinations for both novel and generic products. Learn more.